The Center for Biosimilars® recaps the top stories for the week of February 17, 2020.
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 17, 2020.
Number 5: A new review article discusses the data relevant to inflammatory bowel disease on biosimilars for anti—tumor necrosis factor inhibitors and urges physicians to consider anti-TNF biosimilars for patients with IBD.
Number 4: Which Medicaid plans benefit the most from benefit from the current drug rebate structure and are incentivized to prescribe branded prescriptions? Researchers used the cost issue of follow-on insulin glargine as well as glatiramer acetate to find out.
Number 3: A crossover study comparing autoinjector and prefilled syringe delivery methods of etanercept biosimilar SB4 shows bioequivalent pharmacokinetic parameters and similar safety profiles following a single administration in healthy men.
Number 2: A pharmaceutical industry veteran and consultant for biosimilar makers discusses the ins and outs of the approvals process that cause frustration and unnecessary expense at the recent Specialty Therapies and Biosimilars Congress.
Number 1: Hurdles to a vibrant biosimilar market are not as insurmountable as they appear, according to Center for Biosimilars contributor Steven Lucio, the associate vice president for the Center for Pharmacy Practice Excellence at Vizient.
To read all of these articles and more, visit centerforbiosimilars.com.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors
November 11th 2023The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.